Carbon ion irradiation of the human prostate cancer cell line PC3: A whole genome microarray study

International Journal of Oncology

Volumn 44, Issue 4, 2014, Pages 1056-1072

  Suetens, Annelies ^a,b   Moreels, Marjan ^a   Quintens, Roel ^a   Chiriotti, Sabina ^a,b   Tabury, Kevin ^a   Michaux, Arlette ^a   Grégoire, Vincent ^b   Baatout, Sarah ^a,c  

^a BELGIAN NUCLEAR RESEARCH CENTRE   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Biomarkers; Carbon ion therapy; Microarray; Motility genes; PC3 prostate adenocarcinoma

Indexed keywords

ACTIN BINDING PROTEIN; CCDC88A PROTEIN, HUMAN; FIBRONECTIN; FN1 PROTEIN, HUMAN; MOLECULAR MOTOR; MYH9 PROTEIN, HUMAN; MYOSIN HEAVY CHAIN; MYOSIN IIB; NEXN PROTEIN, HUMAN; NONMUSCLE MYOSIN TYPE IIB HEAVY CHAIN; RHO KINASE; ROCK1 PROTEIN, HUMAN; TUMOR MARKER; VESICULAR TRANSPORT PROTEIN;

BIOSYNTHESIS; CELL MOTION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; HUMAN; ION THERAPY; MALE; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; PROSTATIC NEOPLASMS; RADIATION RESPONSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION; TUMOR RECURRENCE;

CELL LINE, TUMOR; CELL MOVEMENT; FIBRONECTINS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEAVY ION RADIOTHERAPY; HUMANS; MALE; MICROFILAMENT PROTEINS; MOLECULAR MOTOR PROTEINS; MYOSIN HEAVY CHAINS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NONMUSCLE MYOSIN TYPE IIB; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; PROSTATIC NEOPLASMS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; VESICULAR TRANSPORT PROTEINS;

EID: 84894429902     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2287     Document Type: Article

References (77)

1. Karger CP and Jäkel O: Current status and new developments in ion therapy. Strahlenther Onkol 183: 295-300, 2007.
2. Krämer M, Weyrather WK and Scholz M: The increased biological effectiveness of heavy charged particles: from radiobiology to treatment planning. Technol Cancer Res Treat 2: 427-436, 2003.
3. Iwadate Y, Mizoe J, Osaka Y, Yamaura A and Tsujii H: High linear energy transfer carbon radiation effectively kills cultured glioma cells with either mutant or wild-type p53. Int J Radiat Oncol Biol Phys 50: 803-808, 2001.
4. Wada S, Kobayashi Y, Funayama T, Natsuhori M, Ito N and Yamamoto K: Detection of DNA damage in individual cells induced by heavy-ion irradiation with an non-denaturing comet assay. J Radiat Res 43 (Suppl): S153-S156, 2002.
5. Hamada N: Recent insights into the biological action of heavy-ion radiation. J Radiat Res 50: 1-9, 2009.
6. Rossi Jr CJ, Slater JD, Reyes-Molyneux N, et al: Particle beam radiation therapy in prostate cancer: is there an advantage? Semin Radiat Oncol 8: 115-123, 1998.
7. Orecchia R, Fossati P and Rossi S: The National Center for Oncological Hadron Therapy: status of the project and future clinical use of the facility. Tumori 95: 169-176, 2009.
8. Ishikawa H, Tsuji H, Kamada T, et al: Carbon-ion radiation therapy for prostate cancer. Int J Urol 19: 296-305, 2012.
9. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
10. Fidler IJ, Kim SJ and Langley RR: The role of the organ microenvironment in the biology and therapy of cancer metastasis. J Cell Biochem 101: 927-936, 2007.
11. Hagen RM and Ladomery MR: Role of splice variants in the metastatic progression of prostate cancer. Biochem Soc Trans 40: 870-874, 2012.
12. Ishikawa H, Tsuji H, Kamada T, et al: Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer. Int J Radiat Oncol Biol Phys 66: 1084-1091, 2006.
13. Wakatsuki M, Tsuji H, Ishikawa H, et al: Quality of life in men treated with carbon ion therapy for prostate cancer. Int J Radiat Oncol Biol Phys 72: 1010-1015, 2008.
14. Akakura K, Tsujii H, Morita S, et al: Phase I/II clinical trials of carbon ion therapy for prostate cancer. Prostate 58: 252-258, 2004.
15. Tsuji H, Yanagi T, Ishikawa H, et al: Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phys 63: 1153-1160, 2005.
16. Vicini FA, Kestin LL and Martinez AA: The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 45: 553-561, 1999.
17. Zietman AL, Bae K, Slater JD, et al: Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 28: 1106-1111, 2010.
18. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
19. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
20. Msaouel P, Pissimissis N, Halapas A and Koutsilieris M: Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract Res Clin Endocrinol Metab 22: 341-355, 2008.
21. Wild-Bode C, Weller M, Rimner A, Dichgans J and Wick W: Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 61: 2744-2750, 2001.
22. Zhou YC, Liu JY, Li J, et al: Ionizing radiation promotes migration and invasion of cancer cells through transforming growth factor-beta-mediated epithelial-mesenchymal transition. Int J Radiat Oncol Biol Phys 81: 1530-1537, 2011.
23. Yao H, Zeng ZZ, Fay KS, et al: Role of α(5)β(1) integrin up-regulation in radiation-induced invasion by human pancreatic cancer cells. Transl Oncol 4: 282-292, 2011.
24. Cordes N, Blaese MA, Meineke V and Van Beuningen D: Ionizing radiation induces up-regulation of functional beta1-integrin in human lung tumour cell lines in vitro. Int J Radiat Biol 78: 347-357, 2002.
25. De Bacco F, Luraghi P, Medico E, et al: Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst 103: 645-661, 2011.
26. Fujita M, Otsuka Y, Yamada S, Iwakawa M and Imai T: X-ray irradiation and Rho-kinase inhibitor additively induce invasiveness of the cells of the pancreatic cancer line, MIAPaCa-2, which exhibits mesenchymal and amoeboid motility. Cancer Sci 102: 792-798, 2011.
27. Mikheeva SA, Mikheev AM, Petit A, et al: TWIST1 promotes invasion through mesenchymal change in human glioblastoma. Mol Cancer 9: 194, 2010.
28. Goetze K, Scholz M, Taucher-Scholz G and Mueller-Klieser W: The impact of conventional and heavy ion irradiation on tumor cell migration in vitro. Int J Radiat Biol 83: 889-896, 2007.
29. Akino Y, Teshima T, Kihara A, et al: Carbon-ion beam irradiation effectively suppresses migration and invasion of human non-small-cell lung cancer cells. Int J Radiat Oncol Biol Phys 75: 475-481, 2009.
30. Ogata T, Teshima T, Kagawa K, et al: Particle irradiation suppresses metastatic potential of cancer cells. Cancer Res 65: 113-120, 2005.
31. Fujita M, Otsuka Y, Imadome K, Endo S, Yamada S and Imai T: Carbon-ion radiation enhances migration ability and invasiveness of the pancreatic cancer cell, PANC-1, in vitro. Cancer Sci 103: 677-683, 2012.
32. Goetze K, Scholz M, Taucher-Scholz G and Mueller-Klieser W: Tumor cell migration is not influenced by p21 in colon carcinoma cell lines after irradiation with X-ray or (12)C heavy ions. Radiat Environ Biophys 49: 427-435, 2010.
33. Sharungbam GD, Schwager C, Chiblak S, et al: Identification of stable endogenous control genes for transcriptional profiling of photon, proton and carbon-ion irradiated cells. Radiat Oncol 7: 70, 2012.
34. Matsumoto Y, Iwakawa M, Furusawa Y, et al: Gene expression analysis in human malignant melanoma cell lines exposed to carbon beams. Int J Radiat Biol 84: 299-314, 2008.
35. Girdhani S, Lamont C, Hahnfeldt P, Abdollahi A and Hlatky L: Proton irradiation suppresses angiogenic genes and impairs cell invasion and tumor growth. Rad Res 178: 33-45, 2012.
36. Fushimi K, Uzawa K, Ishigami T, et al: Susceptible genes and molecular pathways related to heavy ion irradiation in oral squamous cell carcinoma cells. Radiother Oncol 89: 237-244, 2008.
37. Higo M, Uzawa K, Kawata T, et al: Enhancement of SPHK1 in vitro by carbon ion irradiation in oral squamous cell carcinoma. Int J Radiat Oncol Biol Phys 65: 867-875, 2006.
38. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF and Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17: 16-23, 1979.
39. Ziegler JF, Ziegler MD and Biersack JP: SRIM - The stopping and range of ions in matter. Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms 268: 1818-1823, 2010.
40. El-Saghire H, Thierens H, Monsieurs P, Michaux A, Vandevoorde C and Baatout S: Gene set enrichment analysis highlights different gene expression profiles in whole blood samples X-irradiated with low and high doses. Int J Radiat Biol 89: 628-638, 2013.
41. Benjamini Y and Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc 57: 289-300, 1995.
42. Hu Z, Bao J and Reecy JM: CateGOrizer: A web-based program to batch analyze Gene Ontology Classification Categories. Online J Bioinformatics 9: 108-112, 2008.
43. Mootha VK, Lindgren CM, Eriksson KF, et al: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267-273, 2003.
44. Subramanian A, Tamayo P, Mootha VK, et al: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550, 2005.
45. Merico D, Isserlin R, Stueker O, Emili A and Bader GD: Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One 5: e13984, 2010.
46. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
47. Gulzar ZG, McKenney JK and Brooks JD: Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1. Oncogene 32: 70-77, 2013.
48. Taylor BS, Schultz N, Hieronymus H, et al: Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22, 2010.
49. Sofia Vala I, Martins LR, Imaizumi N, et al: Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS One 5: e11222, 2010.
50. Pickhard AC, Margraf J, Knopf A, et al: Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways. BMC Cancer 11: 388, 2011.
51. Isaacs WB, Carter BS and Ewing CM: Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51: 4716-4720, 1991.
52. Leiss M, Beckmann K, Giros A, Costell M and Fässler R: The role of integrin binding sites in fibronectin matrix assembly in vivo. Curr Opin Cell Biol 20: 502-507, 2008.
53. Oppenheimer SB: Cellular basis of cancer metastasis: A review of fundamentals and new advances. Acta Histochem 108: 327-334, 2006.
54. Ding J, Li D, Wang X, Wang C and Wu T: Fibronectin promotes invasiveness and focal adhesion kinase tyrosine phosphorylation of human colon cancer cell. Hepatogastroenterology 55: 2072-2076, 2008.
55. Qian P, Zuo Z, Wu Z, et al: Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis. Cancer Res 71: 6463-6474, 2011.
56. Nam JM, Onodera Y, Bissell MJ and Park CC: Breast cancer cells in three-dimensional culture display an enhanced radio-response after coordinate targeting of integrin alpha5beta1 and fibronectin. Cancer Res 70: 5238-5248, 2010.
57. Andarawewa KL, Erickson AC, Chou WS, et al: Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition. Cancer Res 67: 8662-8670, 2007.
58. Yang HJ, Kim N, Seong KM, Youn H and Youn B: Investigation of radiation-induced transcriptome profile of radioresistant non-small cell lung cancer A549 cells using RNA-seq. PLoS One 8: e59319, 2013.
59. Hei TK, Zhao YL, Roy D, Piao CQ, Calaf G and Hall EJ: Molecular alterations in tumorigenic human bronchial and breast epithelial cells induced by high LET radiation. Adv Space Res 27: 411-419, 2001.
60. Liu C, Xue H, Lu Y and Chi B: Stem cell gene Girdin: a potential early liver metastasis predictor of colorectal cancer. Mol Biol Rep 39: 8717-8722, 2012.
61. Narumiya S, Tanji M and Ishizaki T: Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 28: 65-76, 2009.
62. Lin SL, Chiang A, Chang D and Ying SY: Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14: 417-424, 2008.
63. Zhai GG, Malhotra R, Delaney M, et al: Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway. J Neurooncol 76: 227-237, 2006.
64. Sandquist JC, Swenson KI, Demali KA, Burridge K and Means AR: Rho kinase differentially regulates phosphorylation of nonmuscle myosin II isoforms A and B during cell rounding and migration. J Biol Chem 281: 35873-35883, 2006.
65. Cai Y, Rossier O, Gauthier NC, et al: Cytoskeletal coherence requires myosin-IIA contractility. J Cell Sci 123: 413-423, 2010.
66. Sellers JR: Myosins: a diverse superfamily. Biochim Biophys Acta 1496: 3-22, 2000.
67. Morimura S, Suzuki K and Takahashi K: Nonmuscle myosin IIA is required for lamellipodia formation through binding to WAVE2 and phosphatidylinositol 3,4,5-triphosphate. Biochem Biophys Res Commun 404: 834-840, 2011.
68. Derycke L, Stove C, Vercoutter-Edouart AS, et al: The role of non-muscle myosin IIA in aggregation and invasion of human MCF-7 breast cancer cells. Int J Dev Biol 55: 835-840, 2011.
69. Garcia-Marcos M, Jung BH, Ear J, Cabrera B, Carethers JM and Ghosh P: Expression of GIV/Girdin, a metastasis-related protein, predicts patient survival in colon cancer. FASEB J 25: 590-599, 2011.
70. Hébrant A, Dom G, Dewaele M, et al: mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch. PLoS One 7: e37807, 2012.
71. Wang W, Zhang W, Han Y, et al: NELIN, a new F-actin associated protein, stimulates HeLa cell migration and adhesion. Biochem Biophys Res Commun 330: 1127-1131, 2005.
72. Amundson SA and Smilenov LB: Integration of biological knowledge and gene expression data for biomarker selection: FN1 as a potential predictor of radiation resistance in head and neck cancer. Cancer Biol Ther 10: 1252-1255, 2010.
73. Liu X, Choy E, Hornicek FJ, et al: ROCK1 as a potential therapeutic target in osteosarcoma. J Orthop Res 29: 1259-1266, 2011.
74. Tseng TY, Sevilla DW, Moul JW and Maloney KE: Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report. Prostate Cancer Prostatic Dis 9: 195-197, 2006.
75. Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Kirkali Z and Montironi R: Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int 102: 1369-1374, 2008.
76. Hansel DE and Epstein JI: Sarcomatoid carcinoma of the prostate: a study of 42 cases. Am J Surg Pathol 30: 1316-1321, 2006.
77. Huan Y, Idrees M, Gribetz ME and Unger PD: Sarcomatoid carcinoma after radiation treatment of prostatic adenocarcinoma. Ann Diagn Pathol 12: 142-145, 2008.